TSHA (Taysha Gene Therapies) 5-Year EBITDA Growth Rate: 44.60% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSHA Taysha Gene Therapies Inc TSHA
33 GF Score
Price $5.02
GF Value $0.53
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Taysha Gene Therapies 5-Year EBITDA Growth Rate?

Taysha Gene Therapies TSHA -2.71% 33 5-Year EBITDA Growth Rate is 44.60% as of Jun. 2026. GuruFocus rates TSHA with a GF Score™ of 33/100 and a GF Value™ of $0.53 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Taysha Gene Therapies's EBITDA per Share for the three months ended in Jun. 2026 was $-0.13.

During the past 3 years, the average EBITDA Per Share Growth Rate was 54.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 44.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Taysha Gene Therapies was 57.50% per year. The lowest was 35.60% per year. And the median was 54.90% per year.

Taysha Gene Therapies  (NAS:TSHA) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Taysha Gene Therapies 5-Year EBITDA Growth Rate Related Terms

TSHA vs KARD, GHRS, VIR: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Taysha Gene Therapies's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taysha Gene Therapies 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Taysha Gene Therapies's 5-Year EBITDA Growth Rate falls into.


TSHA
33GF Score
Taysha Gene Therapies Inc TSHA
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taysha Gene Therapies 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 44.60% mean?
Taysha Gene Therapies (TSHA) has a 5-Year EBITDA Growth Rate of 44.60% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Taysha Gene Therapies and its competitors.
Is Taysha Gene Therapies' 5-Year EBITDA Growth Rate too high?
Taysha Gene Therapies' current 5-Year EBITDA Growth Rate is 44.60%. Overall, Taysha Gene Therapies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' 5-Year EBITDA Growth Rate compare to KARD and GHRS?
Taysha Gene Therapies' 5-Year EBITDA Growth Rate of 44.60% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Taysha Gene Therapies and its competitors. Taysha Gene Therapies's current 5-Year EBITDA Growth Rate is 44.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.53, compared to a current price of $5.02 — trading 847.2% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 44.60%. Taysha Gene Therapies' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current 5-Year EBITDA Growth Rate is 44.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taysha Gene Therapies (TSHA) Overvalued in 2026?

Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued. The current stock price of $5.02 is trading 847.2% above its estimated GF Value™ of $0.53. GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.

Key valuation signals for TSHA:

  • 5-Year EBITDA Growth Rate: 44.60%
  • GF Value™: $0.53 vs. price of $5.02 (847.2% above fair value)
  • GF Score™: 33/100 with 2 warning signs

No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taysha Gene Therapies Business Description

Address 3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
33GF Score

Get the complete analysis for TSHA

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.02
Price
$0.53
GF Value